跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Nrf2/ARE activators
首页
药物
Nrf2/ARE activators
Nrf2/ARE activators
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
ISOQUINILINE NRF2 AGONISTS
EP 4139294 B1
申请人: C4X DISCOVERY LTD
优先权: 2020
CN
EP
US
WO
4 件公开
COMPOSITIONS COMPRISING EXEMESTANE AND NOVEL METHODS OF USE
US 2015025049 A1
申请人: UNIV JOHNS HOPKINS
优先权: 2013
US
WO
4 件公开
COMPOSITIONS AND METHODS FOR ACTIVATING NRF2-DEPENDENT GENE EXPRESSION
EP 3863723 A4
申请人: UNIV CHICAGO
优先权: 2018
EP
US
3 件公开
Therapeutic compounds
US 12098148 B2
申请人: C4X DISCOVERY LTD
优先权: 2018
CN
US
3 件公开
THERAPEUTICS FOR NEUROLOGICAL DISORDERS
US 2011251230 A1
申请人: UNIV SHEFFIELD
优先权: 2008
CN
US
2 件公开
NRF2 Deficiency Influences Susceptibility to Steroid Resistance via HDAC2 Reduction
US 2014080795 A1
申请人: RAHMAN IRFAN
优先权: 2010
US
WO
2 件公开
Targeting of Histone Deacetylase 2, Protein Kinase CK2, and Nuclear Factor NRF2 For Treatment of Inflammatory Diseases
US 2012022129 A1
申请人: RAHMAN IRFAN
优先权: 2011
US
COMPOSITIONS AND METHODS OF TREATMENT OF CORNEAL ENDOTHELIUM DISORDERS
US 2013288985 A1
申请人: JURKUNAS ULA V
优先权: 2011
US
Small molecule activators of NRF2 pathway
US 9737525 B2
申请人: MASSACHUSETTS GEN HOSPITAL
优先权: 2014
US
Tetrahydronaphthalene derivatives useful as Nrf2 activators
US 11465963 B2
申请人: BIOGEN MA INC
优先权: 2017
US
第 1 / 2 页
上一页
下一页
药物
反馈